Why GW Pharmaceuticals Stock Is Up Today

What happened?
Shares of GW Pharmaceuticals (NASDAQ:GWPH) are up by 4.8% as of 3:18 p.m. EDT on Monday,
after rising by as much as 5.5% earlier in the day. The catalyst for these nice gains is the fact that
the U.S. Food and Drug Administration (FDA) approved GW Pharma's Epidiolex for the treatment
of seizures associated with tuberous sclerosis complex (TSC).

So what
Back in June of 2018, Epidiolex was approved for the treatment of seizures associated with
Lennox-Gastaut syndrome (LGS) and Dravet syndrome, thus becoming the first cannabis-derived
drug to be approved by the FDA. And although Epidiolex had a successful first year (or so) on
the market, the drug's quarter-over-quarter sales growth has been slowing noticeably.
Thanks to this new indication, Epidiolex's sales growth will likely increase in the coming quarters.

Now what
With today's gains, GW Pharma's stock is up by almost 28% year to date. The company could
continue to outperform the market, especially if the launch of Epidiolex as a treatment for seizures
associated with TSC is as successful as its initial launch was. In short, now may be a good time to
consider buying shares of GW Pharma.

Read more news before anyone else here. : เกมสล็อตออนไลน์